Starpharma 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
6 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD0466 / AstraZeneca
2020-005106-25: A Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD0466 in Patients with Advanced Haematological Malignancies

Not yet recruiting
1/2
168
Europe
AZD0466 powder for concentrate for solution for infusion, AZD0466, Powder and solvent for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Advanced Haematological Malignancies, Blood cancer, Diseases [C] - Cancer [C04]
 
 
2021-003410-39: Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 in Patients with Advanced Non-Hodgkin Lymphoma Evaluar la Seguridad, Tolerabilidad, Farmacoquinética y Eficacia Preliminar de AZD0466 en Pacientes con Linfoma no Hodgkin Avanzado

Not yet recruiting
1/2
49
Europe
AZD0466 powder for concentrate for solution for infusion, AZD0466, Powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Advanced Non-Hodgkin Lymphoma Linfoma no Hodgkin avanzado, Lymphoma Linfoma, Diseases [C] - Cancer [C04]
 
 
NIMBLE, NCT04865419 / 2020-005106-25: Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Terminated
1
46
Europe, US, RoW
AZD0466, Voriconazole
AstraZeneca, AstraZeneca AB
Haematological Malignancies
08/23
08/23
NCT05205161 / 2021-003410-39: A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Terminated
1
7
Europe, US, RoW
AZD0466
AstraZeneca, AstraZeneca AB
Non-Hodgkin Lymphoma
08/23
08/23
dendrimer docetaxel (DEP docetaxel) / Starpharma
2016-000877-19: A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.

Ongoing
1/2
65
Europe
DTX-SPL8783, Concentrate for solution for infusion, Powder and solution for solution for injection
Starpharma Pty Ltd., Starpharma Pty Ltd.
Locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC)., Advanced malignant solid tumours., Diseases [C] - Cancer [C04]
 
 
2019-004332-36: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients with Advanced Malignancies

Not yet recruiting
1/2
63
Europe
DTX-SPL8783, Gemcitabine, DTX-SPL8783, Powder for solution for infusion, Gemcitabine
Starpharma Pty Ltd, Starpharma Pty Ltd
Advanced malignant solid tumours, Advanced malignant solid tumours, Diseases [C] - Cancer [C04]
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
AZD0466 / AstraZeneca
2020-005106-25: A Study to Assess the Safety, Tolerability, Pharmacokinetics of AZD0466 in Patients with Advanced Haematological Malignancies

Not yet recruiting
1/2
168
Europe
AZD0466 powder for concentrate for solution for infusion, AZD0466, Powder and solvent for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Advanced Haematological Malignancies, Blood cancer, Diseases [C] - Cancer [C04]
 
 
2021-003410-39: Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of AZD0466 in Patients with Advanced Non-Hodgkin Lymphoma Evaluar la Seguridad, Tolerabilidad, Farmacoquinética y Eficacia Preliminar de AZD0466 en Pacientes con Linfoma no Hodgkin Avanzado

Not yet recruiting
1/2
49
Europe
AZD0466 powder for concentrate for solution for infusion, AZD0466, Powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Advanced Non-Hodgkin Lymphoma Linfoma no Hodgkin avanzado, Lymphoma Linfoma, Diseases [C] - Cancer [C04]
 
 
NIMBLE, NCT04865419 / 2020-005106-25: Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies

Terminated
1
46
Europe, US, RoW
AZD0466, Voriconazole
AstraZeneca, AstraZeneca AB
Haematological Malignancies
08/23
08/23
NCT05205161 / 2021-003410-39: A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma

Terminated
1
7
Europe, US, RoW
AZD0466
AstraZeneca, AstraZeneca AB
Non-Hodgkin Lymphoma
08/23
08/23
dendrimer docetaxel (DEP docetaxel) / Starpharma
2016-000877-19: A phase 1/2 study in which, DTX-SPL8783, the trial medication will beadministered (alone or in combination with nintedanib) in order to assess the safety, tolerability, pharmacokinetics (distribution of DTX-SPL8783 in the body) and efficacy in patients with advanced malignant tumours.

Ongoing
1/2
65
Europe
DTX-SPL8783, Concentrate for solution for infusion, Powder and solution for solution for injection
Starpharma Pty Ltd., Starpharma Pty Ltd.
Locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC)., Advanced malignant solid tumours., Diseases [C] - Cancer [C04]
 
 
2019-004332-36: A Phase 1/2 Modular, Multi-Arm Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of DTX-SPL8783 (DEP docetaxel/DEP-DTX) in Combination with Anti-Cancer Treatments, in Patients with Advanced Malignancies

Not yet recruiting
1/2
63
Europe
DTX-SPL8783, Gemcitabine, DTX-SPL8783, Powder for solution for infusion, Gemcitabine
Starpharma Pty Ltd, Starpharma Pty Ltd
Advanced malignant solid tumours, Advanced malignant solid tumours, Diseases [C] - Cancer [C04]
 
 

Download Options